FNIH Study Shows Promise of Blood Tests for Alzheimer’s Disease, featuring Dementia Expert Dr. Schindler and FNIH Neuroscience Director Dr. Travaglia

In this episode, Ayesha spoke with Alessio Travaglia, PhD, neuroscientist and Director Neuroscience at the Foundation for the National Institutes of Health (FNIH) and Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University.

Results from a head-to-head study led by the FNIH Biomarkers Consortium, with data analysis led by Dr. Schindler, have shown that some commercial diagnostic blood tests are accurate enough for clinical use and could replace cerebrospinal fluid (CSF) tests and PET scans in the near future for the diagnosis of Alzheimer’s disease. This would save patients the cost and pain associated with these traditional diagnostic approaches. The findings were presented at the Alzheimer’s Association International Conference (AAIC) in Philadelphia recently.

The findings could improve clinical diagnosis and speed future drug development by helping researchers select optimal clinical trial participants.

Tune into the episode to hear from Dr. Schindler and Dr. Travaglia about the promise of the blood tests for Alzheimer’s diagnosis.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/Follow Us on Social Media

Twitter: https://twitter.com/XtalksInstagram: https://www.instagram.com/xtalks/Facebook: https://www.facebook.com/Xtalks.Webinars/LinkedIn: https://www.linkedin.com/company/xtalks-webconferencesYouTube: https://www.youtube.com/c/XtalksWebinars/featured